pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

241 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints579BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps22
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • <![CDATA[GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026]]>
    <![CDATA[We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Unmet Needs in Endometrial Cancer]]>
    <![CDATA[Important unmet needs remain in endometrial cancer even as antibody drug conjugates begin to expand the therapeutic armamentarium.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCs]]>
    <![CDATA[In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper exp…
    onclive · 2mo ago
← prev
page 7 of 10
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
↗ source
  • <![CDATA[Future Directions in Relapsed and Refractory Multiple Myeloma ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer ]]>
    <![CDATA[Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Sequencing Strategies After Progression in Multiple Myeloma ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy]]>
    <![CDATA[In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung…
    onclive · 2mo ago↗ source
  • <![CDATA[Sequencing ADCs in Endometrial Cancer]]>
    <![CDATA[Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Second Clinical Scenario - Progressive Disease Despite Hematocrit Control]]>
    <![CDATA[Polycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Real-World Data Highlight Survival Benefit of Rituximab Maintenance After Frontline BR in MCL]]>
    <![CDATA[Rituximab following first-line bendamustine demonstrated significant OS and EFS real-world benefits in mantle cell lymphoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Silbermann on Clinical Trial Design Considerations in Multiple Myeloma]]>
    <![CDATA[Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL]]>
    <![CDATA[Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors]]>
    <![CDATA[Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[INBRX-106 Plus Pembrolizumab Yields Efficacy Benefit vs Pembrolizumab Alone in First-Line HNSCC]]>
    <![CDATA[First-line INBRX-106 plus pembrolizumab generated a higher ORR vs pembrolizumab monotherapy in PD-L1–positive metastatic or unresectable HNSCC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Treatment Intensification Gains Momentum in mCSPC Management]]>
    <![CDATA[During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approval of Brexu-Cel for R/R MCL Calls for Raised Awareness of CAR T-Cell Therapy Safety Considerations]]>
    <![CDATA[Luhua (Michael) Wang, MD, discusses the FDA approval of brexu-cel in mantle cell lymphoma and what to know about CAR T-cell therapy in clinical practice.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCT]]>
    <![CDATA[R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Renal Cell Carcinoma: Real-World Factors in First-Line Treatment Selection]]>
    <![CDATA[In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Expanding ctDNA Applications to RCC and Germ Cell Tumors]]>
    <![CDATA[Experts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[RAPNO Criteria and MRI Assessment in PLGG: Recommendations vs. Real-World Practice]]>
    <![CDATA[Learn how clinicians weigh symptoms, MRI changes and family goals to decide when a child’s tumor needs treatment—beyond simple size cutoffs.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[ctDNA in Metastatic Urothelial Carcinoma]]>
    <![CDATA[Experts explain how ctDNA tracking in metastatic cancer helps tailor immunotherapy, spot relapse early, and guide dose breaks—plus key limitations.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Institutional Perspectives on Treatment Thresholds in PLGG]]>
    <![CDATA[Experts weigh PLGG treatment choices, balancing chemo and MEK inhibitors, guided by vision decline, symptoms, tumor growth, and family logistics.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Renal Cell Carcinoma: Practical Treatment Selection Across Risk Groups]]>
    <![CDATA[In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians approach treatment selection in renal cell carcinoma across diffe…
    onclive · 2mo ago↗ source
  • <![CDATA[Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer]]>
    <![CDATA[The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Five Under 5: Top Oncology Videos for the Week of 5/3]]>
    <![CDATA[The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.]]>
    onclive · 2mo ago↗ source